Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting

Slides:

Advertisements

Similar presentations

Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

Advertisements

What is the Optimal Approach to CLL, BR vs. FCR/FR?

Randomized phase 3 study of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in newly diagnosed.

Goede V et al. Proc ASCO 2013;Abstract 7004.

Does Chlorambucil Add to Obinutuzumab in the Treatment of the Unfit CLL Patient? NO Richard R. Furman, MD CLL Research Center.

CORAL: COllaborative trial in Relapsed Aggressive Lymphoma R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed.

Presented By Patrick Wen at 2014 ASCO Annual Meeting

Presented By Raymond Huang at 2014 ASCO Annual Meeting

CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma.

Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS , ONO-4538) and ipilimumab (IPI) concurrent.

Prevention of Early Menopause Study (POEMS)-S0230 Phase III trial of LHRH analog during chemotherapy to reduce ovarian failure in early stage, hormone.

A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy Presented By Eudocia Lee at 2014.

Eastern cooperative oncology group E1496: ECOG and CALGB Cyclophosphamide/Fludarabine (CF) with or without Maintenance Rituximab (MR) in Advanced Indolent.

Randomized Comparison of Ibrutinib Versus Ofatumumab in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the.

The Clinical Trials of HDC/ABMT in Women with Breast Cancer Prof Cindy Farquhar MD MPH University of Auckland, NZ.

Pancreatic Cancer Ali Shamseddine MD Proessor of Medicine AUBMC

Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS , ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi.

A phase 3, multicenter, randomized, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid.

A Randomized Phase 2 Trial Comparing Efficacy of the Combination of the PARP-inhibitor Olaparib and the Anti-angiogenic Cediranib Against Olaparib Alone.

A Randomized Phase II Study Comparing Consolidation with a Single Dose of 90 Y Ibritumomab Tiuxetan (Zevalin ® ) (Z) vs Maintenance with Rituximab (R)

Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris.

Dyer MJS et al. Proc ASH 2014;Abstract 1743.

Rituximab plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in.

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Safety and Efficacy of Abbreviated Induction with Oral Fludarabine (F) and Cyclophosphamide (C) Combined with Dose-Dense IV Rituximab (R) in Previously.

Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) versus Bendamustine and Rituximab (BR) in Previously Untreated and.

Slide 1 Presented By Christian Hinrichs at 2014 ASCO Annual Meeting.

Rituximab Maintenance After Chemoimmunotherapy Induction in 1 st and 2 nd Line Improves Progression Free Survival: Planned Interim Analysis of the International.

Slide 1 Presented By Jan Buckner at 2014 ASCO Annual Meeting.

Presented By Michael Overman at 2016 ASCO Annual Meeting

CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 GOG0213: Bevacizumab Retreatment of Recurrent Platinum-Sensitive Ovarian.

Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab or.

Presented By Shin Fujita at 2016 ASCO Annual Meeting

May 29 - June 2, 2015 CR Rate at 30 Mos Is a Feasible Surrogate Endpoint for PFS in First-line Follicular Lymphoma Trials CCO Independent Conference Highlights.

R3 이운주/Prof 맹치훈. Introduction Pancreatic adenocarcinoma is most lethal cancer, with a 5-year survival rate of less than 5%. Relapsed occurs in 80-85%

12 th Annual CTOS Meeting 2006 SINGLE AGENT DOXORUBICIN VS DOSE INTENSIVE COMBINATION THERAPY WITH EPIRUBICIN / IFOSFAMIDE IN PREVIOUSLY UNTREATED ADULT.

Geisler C et al. Proc ASH 2011;Abstract 290.

Presented By Lorenz Trumper at 2016 ASCO Annual Meeting

GEM2005MAS65 Trial: Bortezomib-Based Maintenance Increases CR Rate and PFS in Elderly Patients With Newly Diagnosed Multiple Myeloma Slideset on: Mateos.

Presented By Michael Lee at 2016 ASCO Annual Meeting

Presented By Mette Van Ramshorst at 2017 ASCO Annual Meeting

Presented By Antoni Ribas at 2014 ASCO Annual Meeting

Presented By Luca Malorni at 2017 ASCO Annual Meeting

Jabbour E et al. Proc ASH 2015;Abstract 83.

Table 1 Baseline patient characteristics

WHAT IS THE BEST Front-Line REGIMEN for Patients With CLL

Fowler NH et al. Proc ASCO 2010;Abstract 8036.

Optimizing the Treatment of Recurrent/Metastatic SCCHN

Prolonging Progression-Free Survival in Follicular Lymphoma

Reviewer: Dr Scott Berry Date posted: June 21, 2007

Best Practices in Chronic Myeloid Leukemia by Multidisciplinary Teams

Novel and Emerging Approaches to Treating CLL

Activity Goals. Activity Goals Case Presentation.

Badoux X et al. Proc ASCO 2010;Abstract 6508.

Selected Highlights of the Latest Advances in PAH

Presented By Johanna Bendell at 2016 ASCO Annual Meeting

Vitolo U et al. Proc ASH 2011;Abstract 777.

Fowler NH et al. Proc ASH 2011;Abstract 99.

Baselga J et al. SABCS 2009;Abstract 45.

Presented By Mathias Rummel at 2016 ASCO Annual Meeting

The Road to Quality Improvement in HER2-Positive Breast Cancer

Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.

Individualizing Therapy for Patients With CLL in the Community Practice Setting: Focus on Age and Comorbidities.

Assessing New Paradigms in CLL: MRD Negativity

FDA-Approved PI3K Inhibitors for CLL and FL

LBA-4 A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy.

An Updated Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated.

Emerging Regimens in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

A Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated Extensive-Stage.

Optimizing Front-Line Endocrine Therapy in Metastatic Breast Cancer

Presentation transcript:

Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting Rituximab maintenance after induction with abbreviated FCR in previously untreated elderly ( 65 years) CLL patients : results of the randomized CLL 2007 SA trial from the French FILO Group Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting

Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting Introduction Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting

Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting Study design - CLL 2007 SA Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting

Methodology and objectives - CLL 2007 SA Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting

Treatment regimen - CLL 2007 SA Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting

Main inclusion - randomization criteria - CLL 2007 SA Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting

Patient disposition - CLL 2007 SA Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting

Patient characteristics - CLL 2007 SA Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting

Patient characteristics - CLL 2007 SA Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting

Patient characteristics - CLL 2007 SA Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting

Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting Safety profile - CLL 2007 SA Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting

Hematologic toxicity - CLL 2007 SA Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting

Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting Second cancers - CLL 2007 SA Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting

Progression-free survival - CLL 2007 SA Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting

Subgroup analysis of progression-free survival - CLL 2007 SA Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting

Overall survival - CLL 2007 SA Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting

Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting Conclusions - CLL 2007 SA Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting

Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting Acknowledgments Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting